A Day of Healthcare Innovation in partnership with Doceree
Doceree participated in SXSW 2025 connecting with global professionals at the forefront of technology and innovation.
In collaboration with FINN Partners and Humble Ventures, Doceree hosted the 'Future of Health Day' event. The event featured discussions on pioneering topics, such as advancements in space medicine, the role of cloud technology in food security, bioengineering solutions to organ shortages, the impact of public-private partnerships on innovation, and the future of pharmaceutical marketing.
Esteemed speakers from the industry their insights, highlighting the significance of these developments in shaping the future of healthcare.
Session 1: Bioengineering Approaches to Solve the US Organ Shortage: Carnegie Mellon University College of Engineering
Moderator: Ritesh Patel, Chief Growth Officer, Doceree
Speakers:
- Keith Cook, David Edward Schramm Professor and Head, Biomedical Engineering (CMU)
- Rosalyn Abbott, Associate Professor, Biomedical Engineering (CMU)
- Adam Feinberg, Professor, Biomedical Engineering and Materials Science & Engineering (CMU)
- C. Burcin Taner, M.D., Chair of the Transplant Center at the Mayo Clinic (Florida)
The discussion began with a focus on the severe organ shortage crisis in the US today, where more than 103,223 people are on the national transplant waiting list, as per data from the Health Resources and Services Administration, US. The severity of the crisis is evident in the fact that 17 people die each day waiting for a transplant, despite more than 48000 transplants performed last year. The panel deliberated on the alarming statistic and what needs to be done to solve the crisis.
A key focus of the discussion was the role of bioengineering in addressing this crisis. The panel highlighted an ongoing collaboration between Carnegie Mellon University and Mayo Clinic, where researchers are working on ex-vivo organ repair and 3D bioprinting. Elaborating on the ex-vivo organ repair technique, the panel discussed how damaged organs are perfused for days to weeks outside the body and then treated outside the body to repair damage, extending their viability for transplantation.
The panel also explored 3D bioprinting as a groundbreaking approach to fabricating functional tissues and organs using living cells, replicating the structure and function of native organs. This could potentially reduce reliance on traditional donors.
Session 2: AI and The Future of Pharma Marketing
Moderator: Kamya Elawadhi, Chief Client Officer, Doceree
Speakers:
- Cozi Namer - VP of Consumer and Clinician Innovation, Pfizer
- Jason Gee, Senior VP, Client Experience at Havas Media
- Jeff McDonald, CEO & Co-Founder at Kythera Labs
The discussion opened with how Artificial Intelligence (AI) is revolutionizing pharmaceutical marketing by enabling personalized engagement, data-driven decision-making, and optimized communication with healthcare professionals (HCPs) and patients.
The panel shared insights on how AI-powered analytics allows pharma companies to better understand HCP behavior, predict preferences, and tailor content accordingly. The recommendations provided by AI-powered analytics can improve real-time HCP interactions, ensuring a more customized and responsive approach.
A key focus of the discussion was how AI processes vast amounts of data to identify market trends and suggest insights, allowing for more precise targeting. AI-driven predictive analytics can help forecast sales, demand, and competitive dynamics, allowing pharmaceutical companies to optimize their strategies effectively. The panel also explored AI as an integral part of healthcare omnichannel marketing, as it analyzes engagement across multiple platforms to ensure the right message is delivered to the right HCP at the right moment.
Another key point of discussion was AI’s role in ensuring regulatory compliance by flagging non-complaint content, thereby reducing risks associated with marketing regulations. The panel concluded that as AI evolves, it will drive further innovation in pharma marketing, providing deeper insights, enhanced customer experiences, and more effective engagement with HCPs and patients.